Abbonarsi

Patient characteristics, care patterns, and outcomes of atrial fibrillation associated hospitalizations in patients with chronic kidney disease and end-stage renal disease - 30/10/21

Doi : 10.1016/j.ahj.2021.06.012 
Nilay Kumar, MD a, Haolin Xu, MS b, Neetika Garg, MD c, Ambarish Pandey, MD d, Roland A Matsouaka, PhD b, e, Michael E Field, MD f, Mintu P Turakhia, MDMAS g, Jonathan P Piccini, MD, MHS b, h, William R Lewis, MD i, Gregg C Fonarow, MD j,
a Division of Hospital Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 
b Duke Clinical Research Institute, Durham, NC 
c Division of Nephrology, University of Wisconsin School of Medicine and Public Health, Madison, WI 
d Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX 
e Department of Biostatistics and Bioinformatics, Duke University, Durham, NC 
f Division of Cardiology, Medical University of South Carolina, Charleston, SC 
g Veterans Affairs Palo Alto Health Care System, Palo Alto, CA; Center for Digital Health, Stanford University School of Medicine, Stanford, CA 
h Division of Cardiology, Duke University Medical Center, Durham, NC 
i Division of Cardiology, MetroHealth System Campus, Case Western Reserve University, Cleveland, OH 
j Division of Cardiology, University of California-Los Angeles, Los Angeles, CA 

Reprint requests: Gregg C. Fonarow, MD, Division of Cardiology, University of California-Los Angeles, 10833 LeConte Ave, Room 47–123 CHS, Los Angeles, CA 90095-1679.Division of CardiologyUniversity of California-Los Angeles10833 LeConte Ave, Room 47–123 CHSLos AngelesCA90095-1679

Riassunto

Background

Chronic Kidney Disease (CKD) and end-stage renal disease (ESRD) are associated with poor outcomes in patients with cardiovascular disease. There is a paucity of contemporary data on in-hospital outcomes and care patterns of atrial fibrillation (AF) associated hospitalizations CKD and ESRD.

Methods

Outcomes and care patterns were evaluated in GWTG-AFIB database (Jan 2013-Dec 2018), including in-hospital mortality, use of a rhythm control strategy, and oral anticoagulation (OAC) prescription at discharge among eligible patients. Generalized logistic regression models with generalized estimating equations were used to ascertain differences in outcomes. Hospital-level variation in OAC prescription and rhythm control was also evaluated.

Results

Among 50,154 patients from 105 hospitals the median age was 70 years (interquartile range 61-79) and 47.3% were women. The prevalence of CKD was 36.0% while that of ESRD was 1.6%. Among eligible patients, discharge OAC prescription rates were 93.6% for CKD and 89.1% for ESRD. After adjustment, CKD and ESRD were associated with higher in-hospital mortality (odds ratio [OR] 3.08, 95% confidence interval [CI] 1.57-6.03 for ESRD and OR 2.02, 95% CI 1.52-2.67 for CKD), lower odds of OAC prescription at discharge (OR 0.59, 95% CI 0.44-0.79 for ESRD and OR 0.84, 95% CI 0.75-0.94 for CKD) compared with normal renal function. CKD was associated with lower utilization of rhythm control strategy (OR 0.92, 95% CI 0.87-0.98) with no significant difference between ESRD and normal renal function (OR 1.32, 95% CI 0.79-1.11). There was large hospital-level variation in OAC prescription at discharge (MOR 2.34, 95% CI 2.05-2.76) and utilization of a rhythm control strategy (MOR 2.69, 95% CI 2.34-3.21).

Conclusions

CKD/ESRD is associated with higher in-hospital mortality, less frequent rhythm control, and less OAC prescription among patients hospitalized for AF. There is wide hospital-level variation in utilization of a rhythm control strategy and OAC prescription at discharge highlighting potential opportunities to improve care and outcomes for these patients, and better define standards of care in this patient population

Il testo completo di questo articolo è disponibile in PDF.

Graphical abstract




Image, graphical abstract

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Atrial fibrillation, End-stage renal disease, Chronic kidney disease, hospitalization, Outcomes Research


Mappa


© 2021  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 242

P. 45-60 - Dicembre 2021 Ritorno al numero
Articolo precedente Articolo precedente
  • Text messages for primary prevention of cardiovascular disease: The TextMe2 randomized clinical trial
  • Harry Klimis, Aravinda Thiagalingam, Daniel McIntyre, Simone Marschner, Amy Von Huben, Clara K. Chow
| Articolo seguente Articolo seguente
  • Cardiac pathology 6 months after hospitalization for COVID-19 and association with the acute disease severity
  • Peder L. Myhre, Siri L. Heck, Julia B. Skranes, Christian Prebensen, Christine M. Jonassen, Trygve Berge, Albulena Mecinaj, Woldegabriel Melles, Gunnar Einvik, Charlotte B. Ingul, Arnljot Tveit, Jan Erik Berdal, Helge Røsjø, Magnus N. Lyngbakken, Torbjørn Omland

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.